Immunogenicity studies of proteins forming the T4 phage head surface. (scientific article)

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines

Q36477537

The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data

Q36692799

The immense journey of bacteriophage T4--from d'Hérelle to Delbrück and then to Darwin and beyond

Q37214042

Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay

Q37336089

Phage as a modulator of immune responses: practical implications for phage therapy

Q38022877

Clinical aspects of phage therapy.

Q38022878

Molecular organization of the head of bacteriophage Teven: underlying design principles

Q40204290

Molecular organization of the shell of the Teven bacteriophage head

Q43782663

Factors influencing the survival and multiplication of bacteriophages in calves and in their environment

Q44036193

Antibodies against staphylococcal bacteriophages in human sera. II. Assay of antibodies in exacerbation and regression of chronic staphylococcal osteomyelitis.

Q45284134

Preparation of endotoxin-free bacteriophages.

Q47300414

Evaluation of CD4+ T cell function In vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization.

Q52025614

Studies on bacteriophage penetration in patients subjected to phage therapy.

Q54768824

Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine

Q56892691

Phage T4 SOC and HOC display of biologically active, full-length proteins on the viral capsid

Q56896793

Antibodies against staphylococcal bacteriophages in human sera. I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections

Q68524797

Immunogenic effect of bacteriophage in patients subjected to phage therapy

Q68718343

The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: reversible and irreversible inactivation

Q73969029

Fate of bacteriophage particles introduced into mice by various routes

Q78297031

Hoc protein regulates the biological effects of T4 phage in mammals

Q79759745

P433

issue

P407

language of work or name

English

Q1860

P304

page(s)

12551-12557

P577

publication date

2014-08-20

P1433

published in

Journal of Virology

Q1251128

P1476

title

Immunogenicity studies of proteins forming the T4 phage head surface

P478

volume

Reverse relations

cites work (P2860)

Q36106493	A Partially Purified Acinetobacter baumannii Phage Preparation Exhibits no Cytotoxicity in 3T3 Mouse Fibroblast Cells
Q26740597	Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics
Q64257131	Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections
Q37360042	Antibody Production in Response to Staphylococcal MS-1 Phage Cocktail in Patients Undergoing Phage Therapy.
Q91644478	Bacteriophage and the Innate Immune System: Access and Signaling
Q64899610	Bacteriophages engineered to display foreign peptides may become short-circulating phages.
Q91900255	Bacteriophages of the lower urinary tract
Q90468698	Bacteriophages: Uncharacterized and Dynamic Regulators of the Immune System
Q92858069	Effect of serum anti-phage activity on colibacillosis control by repeated phage therapy in broilers
Q58591012	Effects of Bacteriophage K on Expression of Cytokines and Activation Markers by Human Dendritic Cells In Vitro
Q96956231	Efficacy of experimental phage therapies in livestock
Q64068083	Genetic Engineering of Bacteriophages Against Infectious Diseases
Q91636186	Impact of Frequent Administration of Bacteriophage on Therapeutic Efficacy in an A. baumannii Mouse Wound Infection Model
Q91707909	Induction of Phage-Specific Antibodies by Two Therapeutic Staphylococcal Bacteriophages Administered per os
Q61813504	Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System
Q37716726	Means to Facilitate the Overcoming of Gastric Juice Barrier by a Therapeutic Staphylococcal Bacteriophage A5/80.
Q39700208	Morphologically Distinct Escherichia coli Bacteriophages Differ in Their Efficacy and Ability to Stimulate Cytokine Release In Vitro
Q39276552	Ménage à trois in the human gut: interactions between host, bacteria and phages
Q36076282	Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood.
Q90176758	Pf Bacteriophage and Their Impact on Pseudomonas Virulence, Mammalian Immunity, and Chronic Infections
Q92641239	Phage Therapy of Pneumonia Is Not Associated with an Overstimulation of the Inflammatory Response Compared to Antibiotic Treatment in Mice
Q28069939	Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases
Q90398229	Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review
Q92468490	Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review
Q40204267	Phage therapy: a realistic weapon against multidrug resistant bacteria
Q90176556	Phage-specific diverse effects of bacterial viruses on the immune system
Q93109078	Phages and Human Health: More Than Idle Hitchhikers
Q38691927	Phages and immunomodulation
Q99234108	Phages and their potential to modulate the microbiome and immunity
Q39249579	Phages in the Human Body
Q40093280	Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages.
Q44666946	Real-Time qPCR as a Method for Detection of Antibody-Neutralized Phage Particles.
Q37092588	T4 Phage Tail Adhesin Gp12 Counteracts LPS-Induced Inflammation In Vivo